ISPOR Task Force report details recommendations for appraising systematic reviews with costs and cost–effectiveness outcomes

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR; NJ, USA) has announced the publication of a Good Practices Report on critically appraising the quality and risk of bias – as well as guidance on how to minimize this risk – in systematic reviews that incorporate costs and cost–effectiveness outcomes. The report, alongside an accompanying checklist incorporating the report’s recommendations, was produced by one of the society’s international Task Force groups and appears in Value in Health. Hans Severens (Erasmus University, Rotterdam, The Netherlands), contributing author and Task Force Co-Chair, explained: “With the increasing number of systematic reviews with costs...

To view this content, please register now for access

It's completely free